Physician profile
Robert S Brown
NPI 1740206796
$4,038.66
in general payments reported to CMS, 2019-2025
13 companies · $3,344 in 2025
The $3,344 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $53.08 · 2021: $53.03 · 2022: $44.09 · 2023: $68.44 · 2024: $259 · 2025: $3,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,035 · Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,035.00 |
| Food and Beverage | $636.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,035.00 | 2025 | Uplizna |
| Sun Pharmaceutical Industries INC. | $329.17 | 2022-2025 | Cequa |
| Allergan, INC. | $186.19 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $149.02 | 2024-2025 | Xiidra, Miebo, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $147.06 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $85.08 | 2019-2021 | |
| Rxsight INC | $26.38 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Alcon Vision LLC | $16.30 | 2025 | Tryptyr |
| Shire North American Group INC | $15.00 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.90 | 2020 | |
| Aerie Pharmaceuticals, INC. | $12.40 | 2020 | |
| Sight Sciences, INC. | $12.33 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.